Global Biopharmaceutical Market to Reach USD 664.8 Billion by 2033, Impelled by Rising Prevalence of Chronic Diseases.

December 02, 2024 | Healthcare

According to the latest report by IMARC Group, titled "Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2025-2033" the global biopharmaceutical market reached a value of USD 326.2 Billion in 2024. Biopharmaceutical refers to a pharmaceutical product that is generally manufactured using various biological sources, including living cells or organisms. Primarily developed in industrial and academic laboratories, it aids in the treatment of several diseases, such as cancers and metabolic disorders. It is widely preferred by healthcare professionals across the globe since it causes minimum side effects to the body, targets only specific molecules, and exhibits high specificity to address various untreatable medical conditions. The demand for biopharmaceutical products is continuously increasing due to the easy accessibility to quality healthcare facilities.

Global Biopharmaceutical Market Trends:

The global market is primarily driven by the rising prevalence of chronic diseases among individuals. This is supported by the sedentary lifestyle led by the masses and the growing geriatric population. Moreover, continuous improvements in biotechnology, along with the increasing investments and funding by numerous public and private firms to upgrade the overall infrastructure, are creating a positive market outlook. Additionally, continual technological advancements, such as the widespread adoption of 3D printing and gene writing as well as the integration of artificial intelligence with supercomputers, are creating lucrative growth opportunities for key players in the biopharmaceutical market. In line with this, extensive research and development (R&D) activities conducted in genetic research are favorably impacting the market growth worldwide. Other factors, including the increasing number of research laboratories and clinical trials across multiple countries and supportive regulations implemented by various governments, are also influencing the growth of the market. On account of the aforementioned factors, the market is anticipated to reach a value of USD 664.8 Billion by 2033, exhibiting a CAGR of 8.2% during 2025-2033.

Market Summary:

  • Based on the indication, the market has been classified into autoimmune diseases, oncology, metabolic disorders and others. 
  • On the basis of the class, the market has been segregated into recombinant proteins, monoclonal antibodies and purified proteins.
  • Based on the region, the market has been divided into North America (the United States and Canada), Latin America (Mexico, Brazil, and Argentina), Europe (Germany, France, Italy, Spain, the United Kingdom, Russia, and Turkey ) and Asia Pacific (Japan, China, Australia, South Korea, India, and Indonesia).
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of these players include AbbVie Inc., Amgen Inc, Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novo Nordisk A/S, Pfizer Inc. and Sanofi S.A.


Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Indications Covered Autoimmune Diseases, Oncology, Metabolic Disorders, Others
Classes Covered Recombinant Proteins, Monoclonal Antibodies, Purified Proteins
Regions Covered North America, Latin America, Europe, Asia Pacific
Countries Covered United States, Canada, Mexico, Brazil, Argentina, Germany, France, Italy, Spain, United Kingdom, Russia, Turkey, Japan, China, Australia, South Korea, India, Indonesia
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter : @imarcglobal

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Biopharmaceutical Market to Reach USD 664.8 Billion by 2033, Impelled by Rising Prevalence of Chronic Diseases.
Purchase Options
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials